Evidence map›Paper›PMID 35380226›Full record

ArticleEuropean radiology2022

Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.

Naik Vietti Violi, Jeffrey Gnerre, Amy Law, Stefanie Hectors, Octavia Bane, John Doucette, Ghadi Abboud, Edward Kim, Myron Schwartz, M Isabel Fiel and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. MRI radiomics andBMC cancer · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Naik Vietti VioliBioMedical Engineering and Imaging Institute, Icahn School of Medicine Mount Sinai, New York, NY, USA.
Jeffrey GnerreDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA.
Amy LawDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA.
Stefanie HectorsBioMedical Engineering and Imaging Institute, Icahn School of Medicine Mount Sinai, New York, NY, USA.
Octavia BaneBioMedical Engineering and Imaging Institute, Icahn School of Medicine Mount Sinai, New York, NY, USA.
John DoucetteDepartment of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghadi AbboudBioMedical Engineering and Imaging Institute, Icahn School of Medicine Mount Sinai, New York, NY, USA.
Edward KimDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA.
Myron SchwartzThe Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
M Isabel FielDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bachir TaouliBioMedical Engineering and Imaging Institute, Icahn School of Medicine Mount Sinai, New York, NY, USA. bachir.taouli@mountsinai.org.ORCID http://orcid.org/0000-0001-6409-1333
Icahn School of Medicine at Mount Sinai · USUniversity of Lausanne · CH

Funding

Schweizerische Zahnärzte-Gesellschaft P2LAP3_178053
6 · The paper itself

Abstract

BACKGROUND AND

aimsTransarterial

methodsThis retrospective study included 48 patients (M/F: 36/12, mean age: 62 years) with HCC treated by TARE followed by surgery with gadoxetate disodium MRI within 90 days of surgery. Two radiologists evaluated tumor response using RECIST1.1, mRECIST, EASL, and LI-RADS-TR criteria and evaluated the percentage of necrosis on subtraction during late arterial, portal venous, and hepatobiliary phases (AP/PVP/HBP). Statistical analysis included inter-reader agreement, correlation between radiologic and pathologic percentage of necrosis, and prediction of CPN using logistic regression and ROC analyses.

resultsHistopathology demonstrated 71 HCCs (2.8 ± 1.7 cm, range: 0.5-7.5 cm) including 42 with CPN, 22 with partial necrosis, and 7 without necrosis. EASL and percentage of tumor necrosis on subtraction at the AP/PVP were independent predictors of CPN (p = 0.02-0.03). Percentage of necrosis, mRECIST, EASL, and LI-RADS-TR had fair to good performance for diagnosing CPN (AUCs: 0.78 - 0.83), with a significant difference between subtraction and LI-RADS-TR for reader 2, and in specificity between subtraction and other criteria for both readers (p-range: 0.01-0.04). Radiologic percentage of necrosis was significantly correlated to histopathologic degree of tumor necrosis (r = 0.66 - 0.8, p < 0.001).

conclusionsPercentage of tumor necrosis on subtraction and EASL criteria were significant independent predictors of CPN in HCC treated with TARE. Image subtraction should be considered for assessing HCC response to TARE when using MRI. KEY POINTS: • Percentage of tumor necrosis on image subtraction and EASL criteria are significant independent predictors of complete pathologic necrosis in hepatocellular carcinoma treated with

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsGadolinium DTPAHumansMagnetic Resonance ImagingMiddle AgedNecrosisRetrospective StudiesYttrium RadioisotopesGadolinium DTPAgadolinium ethoxybenzyl DTPAYttrium-90Yttrium RadioisotopesEmbolizationGadoxetate disodiumHepatocellular carcinomaMagnetic resonance imagingYttrium radioisotopes

Identifiers

PMID35380226
OpenAlexW4225470073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.